About eTheRNA
eTheRNA is a company based in Niel (Belgium) founded in 2013 by Kris Thielemans. eTheRNA has raised $103.94 million across 8 funding rounds from investors including BNP Paribas Fortis, EQT and PMV. eTheRNA offers products and services including LNP Formulation Platform and mRNA Chemistry Platform. eTheRNA operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Niel, Belgium
- Founders Kris Thielemans
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Etherna Immunotherapies
-
Annual Revenue
$1.57 M (USD)430as on Dec 31, 2019
-
Net Profit
-$10.34 M (USD)18as on Dec 31, 2019
-
EBITDA
Not available
-
Total Equity Funding
$103.94 M (USD)
in 8 rounds
-
Latest Funding Round
$38.95 M (USD), Series B
Aug 23, 2022
-
Investors
BNP Paribas Fortis
& 13 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of eTheRNA
eTheRNA offers a comprehensive portfolio of products and services, including LNP Formulation Platform and mRNA Chemistry Platform.
Provides tailored LNP formulations for targeted RNA delivery.
Enables sequence engineering for optimal mRNA stability and efficiency.
People of eTheRNA
Unlock access to complete
Unlock access to complete
Funding Insights of eTheRNA
eTheRNA has successfully raised a total of $103.94M across 8 strategic funding rounds. The most recent funding activity was a Series B round of $38.95 million completed in August 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in eTheRNA
eTheRNA has secured backing from 14 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include BNP Paribas Fortis, EQT and PMV.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare investments are targeted by Boehringer Ingelheim Venture Fund.
|
Locked | Locked | Locked | |
|
Venture capital firm
|
Locked | Locked | Locked | |
|
Venture capital firm focused on multiple sectors
|
Locked | Locked | Locked |
Investor details for eTheRNA
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by eTheRNA
Investment portfolio details for eTheRNA
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - eTheRNA
Detailed financials for eTheRNA
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Etherna Comparisons
Peer comparison for eTheRNA
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of eTheRNA
eTheRNA operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of eTheRNA
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Etherna
Complete news archive for eTheRNA
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about eTheRNA
eTheRNA was founded in 2013 and raised its 1st funding round 3 years after it was founded.
eTheRNA is headquartered in Niel, Belgium. It is registered at Niel, Antwerp, Belgium.
eTheRNA is a funded company, having raised a total of $103.94M across 8 funding rounds to date.
Annual revenue of eTheRNA is $1.57M as on Dec 31, 2019.
eTheRNA was founded in 2013 and is based in Niel, Belgium, where mRNA-based immunotherapies for cancer and infectious diseases are developed. Proprietary TriMix technology is employed, featuring three mRNA moleculescaTLR4, CD40L, and CD70that enhance immune responses via the dendritic cell pathway. Focus is placed on applications for melanoma and breast cancer within the biotechnology sector.
eTheRNA's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
eTheRNA offers LNP Formulation Platform and mRNA Chemistry Platform.
eTheRNA has 14 investors. Key investors include BNP Paribas Fortis, EQT, PMV, European Union, and Life Sciences Partners.